https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king-en.html Drugnews｜藥時事 en 2026-08-19T00:00:00.000Z Just $74 Million Short: Can Skyrizi Succeed Humira as the Autoimmune Drug King? https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king.html Drugnews｜藥時事 zh-tw 2026-08-19T00:00:00.000Z 55 億美元只差一步：Skyrizi 要接棒 Humira 當自體免疫藥王？ https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king-en.html Drugnews｜藥時事 en 2026-08-18T00:00:00.000Z Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King? https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king.html Drugnews｜藥時事 zh-tw 2026-08-18T00:00:00.000Z 一季狂賣 230 億美元，禮來卻急著買下一個藥王